Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)

NCT04715932 is registered in ClinicalTrials.gov with Montreal Heart Institute as lead sponsor.

NCT NCT04715932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04715932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Hesperidin Therapy on COVID-19 Symptoms: The Hesperidin Coronavirus Study (Hesperidin)
Lead sponsor
Montreal Heart Institute
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2021
Completion date
June 7, 2021
Enrollment
216 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anosmia, confusion, cough, covid19, fever, headache, irritable mood, muscle weakness, nausea, pain, pain, abdominal, pain, chest, pain, joint, pain, muscle, shortness of breath, sore throat, vomiting